New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

›ETF Issuers›E Fund Management›03186

03186

E Fund (HK) Solactive Biopharma Select Index ETF

Passive ETF Equity

Not rated

The 03186 Exchange Traded Fund (ETF) is provided by E Fund Management. It is built to track an index: Solactive Biopharma Select Index. The 03186 ETF provides physical exposure, so by buying it you actually own parts of all the 100 underlying holdings. This share class generates a stream of income by distributing dividends.

HK$13.28

N/A

Data as of 10/29/26

1D price range

N/A

52W price range

N/A

YTD Perf.

-9.25%

YTD Flows

Annualized volatility

Fund AuM

€3.2M

Share class AuM

€3.2M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

HK0001254553

TER

0.9%

Inception date

3/23/2026

Issuer

E Fund Management

Benchmark

Solactive Biopharma Select Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

No content available for this fund

API

PerformanceMar 23, 2026 - Oct 29, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 09/30/26

Healthcare

95.88%

Unavailable

4.12%

Latest 03186 news

No content available for this fund

FAQ about 03186

03186 is a passively managed ETF. This ETF provides exposure to Equally Weighted Biotechnology Equities.

03186 tracks the Solactive Biopharma Select Index - HKD, through a full replication replication method.

03186 carries a total expense ratio (TER) of 0.9%.

03186 was introduced to the market on March 23, 2026.

E Fund (HK) Solactive Biopharma Select Index ETF, 03186, is provided by E Fund Management. Learn more about E Fund Management here.

03186 oversees €3.2M in assets as of October 29, 2026.

03186 follows a distributing dividend policy, meaning it pays out income to investors.

As of September 30, 2026, 03186 has significant geographic allocations in China, USA and Hong Kong.

As of September 30, 2026, 03186 focuses largely on Healthcare.

As of September 30, 2026, 03186 holds 100 positions in its portfolio, with 36.05% of assets concentrated in its top 15 holdings.

As of September 30, 2026, 03186 top three holdings include Metis TechBio Co., Ltd., CanSino Biologics, Inc. and InSilico Medicine Cayman TopCo.

The base currency of 03186 is HKD.

Top 10 holdings

Data as of 09/30/26

Metis TechBio Co., Ltd.

2.82%

CanSino Biologics, Inc.

2.75%

InSilico Medicine Cayman TopCo

2.69%

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

2.49%

Duality Biotherapeutics, Inc.

2.45%

Livzon Pharmaceutical Group, Inc.

2.43%

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

2.36%

Akeso, Inc.

2.33%

Shanghai Junshi Biosciences Co., Ltd.

2.32%

Keymed Biosciences, Inc.

2.28%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Don’t Miss a Move in the ETF Market

E Fund (HK) Solactive Biopharma Select Index ETF

FAQ about 03186

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US